Stock News

It’s been a crucial week for Halozyme Therapeutics, Inc. (NASDAQ:HALO); here’s what analysts have to say.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment decreased to 0.95 in Q2 2018. Its down 0.56, from 1.51 in 2018Q1. It dived, as 25 investors sold Halozyme Therapeutics, Inc. shares while 59 reduced holdings. 25 funds opened positions while 55 raised stakes. 118.72 million shares or 0.69% less from 119.54 million shares in 2018Q1 were reported.
M&T Bancorp invested in 0% or 34,362 shares. Farr Miller Washington Limited Liability Dc stated it has 43,417 shares. New York-based American Gru has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Group Inc One Trading Ltd Partnership accumulated 46,976 shares. Adams Diversified Equity Fund stated it has 29,900 shares. Dixon Hubard Feinour Brown Va has 16,702 shares for 0.08% of their portfolio. Bb Biotech Ag owns 8.25M shares or 4.02% of their US portfolio. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Doheny Asset Management Ca holds 148,480 shares or 1.36% of its portfolio. Jacobs Levy Equity reported 312,630 shares. Third Security Ltd Liability holds 17.29M shares or 23.42% of its portfolio. The Missouri-based Piermont Capital Mgmt has invested 0.12% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Apg Asset Nv stated it has 11,300 shares or 0% of all its holdings. Proshare Advisors Ltd Company stated it has 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Voya Mngmt Limited Liability Corp reported 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 4 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Halozyme Therapeutics had 4 analyst reports since May 11, 2018 according to SRatingsIntel. Barclays Capital downgraded the stock to “Underweight” rating in Friday, May 11 report. The rating was maintained by Canaccord Genuity with “Buy” on Monday, May 14. BMO Capital Markets maintained the stock with “Market Perform” rating in Wednesday, August 8 report. Below is a list of Halozyme Therapeutics, Inc. (NASDAQ:HALO) latest ratings and price target changes.

23/08/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $27 Initiates Coverage On
08/08/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $19 New Target: $21 Maintain
14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade

The stock decreased 2.22% or $0.36 during the last trading session, reaching $15.89. About 781,513 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.24% since November 10, 2017 and is uptrending. It has outperformed by 16.62% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.28 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It has a 30.38 P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: which released: “Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics …” on October 17, 2018, also with their article: “Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and …” published on November 08, 2018, published: “The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos …” on November 06, 2018. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: and their article: “Premarket analyst action – healthcare” published on October 19, 2018 as well as‘s news article titled: “A Preview Of Halozyme Therapeutics Q3 Earnings” with publication date: November 06, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *